BIL 010t

Drug Profile

BIL 010t

Alternative Names: Anti-nf-P2X7 antibody; BIL010t; BSCT 10% ointment

Latest Information Update: 02 Jun 2016

Price : $50

At a glance

  • Originator Biosceptre International; Peptech UK
  • Developer Biosceptre International
  • Class Antibodies
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Basal cell cancer

Most Recent Events

  • 31 May 2016 Biosceptre plans a phase II trial for Basal cell cancer in the United Kingdom
  • 22 Jul 2014 Phase-I clinical trials in Basal cell cancer in Australia (Topical) prior to July 2014
  • 22 Jul 2014 Efficacy, safety and immunogenicity data from a phase I trial in Basal cell cancer released by Biosceptre
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top